RxDoctor Payments Data

Jennifer Marbella, MD

Family Medicine · Las Vegas, NVNPI 1073928651

Payments from drug & device makers

$325in general payments, 2019–2025

Across 20 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$113
  • Boehringer Ingelheim$53
  • Daiichi Sankyo Inc.$44
  • Pfizer$40
  • GSK$30
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$20
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$325100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$325 in reported general payments places this provider in the 45th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$11,391
Medicare patients
58
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$82,397
EliquisApixaban62$55,463
OzempicSemaglutide21$29,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,026
MyrbetriqMirabegron15$13,989
Breo ElliptaFluticasone/Vilanterol19$11,124
Arnuity ElliptaFluticasone Furoate29$9,285
Atorvastatin Calcium557$5,065
Albuterol Sulfate HfaAlbuterol Sulfate211$4,642
Omeprazole169$3,802
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$3,612
SymbicortBudesonide/Formoterol Fumarate11$3,293
Gabapentin225$3,089
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,575
Humalog Kwikpen U-100Insulin Lispro11$2,532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$53$82,39767 claims
PfizerEliquis$40$55,46362 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$30$35,43464 claims
Novo NordiskOzempic$113$29,85821 claims
AstraZenecaSymbicort$12$3,29311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →